Department of Oncology and Brachytherapy, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum, Romanowskiej 2 St, ,85-796, Bydgoszcz, Poland.
Department of Radiotherapy, Unit of Radiosurgery and Radiotherapy of CNS, Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland.
Radiat Oncol. 2019 Mar 4;14(1):37. doi: 10.1186/s13014-019-1241-0.
Subventricular zone (SVZ) involvement is associated with a dismal prognosis in patients with glioblastoma multiforme (GBM). Dual-time point (dtp) O-(2-[F]fluoroethyl)-L-tyrosine (FET) PET/CT (PET) may be a time- and cost-effective alternative to dynamic FET PET, but its prognostic value, particularly with respect to SVZ involvement, is unknown.
Thirty-five patients had two scans 5-15 and 50-60 min after i.v. FET injection to define tumor volumes and SVZ involvement before starting radiotherapy. Associations between clinical progression markers, MRI- and dtp FET PET-based tumor volumes, or SVZ involvement and progression-free (PFS) and overall survival (OS) were assessed in univariable and multivariable analyses.
The extent of resection was not related to outcomes. Albeit non-significant, dtp FET PET detected more SVZ infiltration than MRI (60% vs. 51%, p = 0.25) and was significantly associated with poor survival (p < 0.03), but PET-T1-Gad volumes were larger in this group (p < 0.002). Survival was shorter in patients with larger MRI tumor volumes, larger PET tumor volumes, and worse Karnofsky performance status (KPS), with fused PET-T1-Gad and KPS significant in multivariable analysis (p < 0.03). Uptake kinetics was not associated with treatment outcomes.
FET PET-based tumor volumes may be useful for predicting worse prognosis glioblastoma. Although the presence of SVZ infiltration is linked to higher PET/MRI-based tumor volumes, the independent value of dtp FET PET parameters and SVZ infiltration as prognostic markers pre-irradiation has not been confirmed.
侧脑室下区(SVZ)的参与与多形性胶质母细胞瘤(GBM)患者的预后不良有关。双时间点(dtp)O-(2-[F]氟乙基)-L-酪氨酸(FET)正电子发射断层扫描/计算机断层扫描(PET)可能是动态 FET PET 的一种具有时间和成本效益的替代方法,但它的预后价值,特别是关于 SVZ 参与的预后价值,尚不清楚。
35 名患者在静脉注射 FET 后 5-15 分钟和 50-60 分钟进行两次扫描,以在开始放射治疗前定义肿瘤体积和 SVZ 参与情况。在单变量和多变量分析中,评估临床进展标志物、MRI 和 dtp FET PET 基于肿瘤体积或 SVZ 参与与无进展生存期(PFS)和总生存期(OS)之间的相关性。
切除范围与结局无关。尽管无统计学意义,但 dtp FET PET 比 MRI 检测到更多的 SVZ 浸润(60%比 51%,p=0.25),并且与不良生存显著相关(p<0.03),但在该组中 PET-T1-Gad 体积更大(p<0.002)。MRI 肿瘤体积较大、PET 肿瘤体积较大、Karnofsky 表现状态(KPS)较差的患者生存期较短,融合的 PET-T1-Gad 和 KPS 在多变量分析中具有统计学意义(p<0.03)。摄取动力学与治疗结果无关。
基于 FET PET 的肿瘤体积可能有助于预测更差的胶质母细胞瘤预后。尽管 SVZ 浸润的存在与更高的基于 PET/MRI 的肿瘤体积相关,但 dtp FET PET 参数和 SVZ 浸润作为放射治疗前的独立预后标志物的价值尚未得到证实。